Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:LA CAB + RPV in San Francisco’s Ward 86 Safety Net Clinic Serving Publicly Insured PWHSOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAFAmanda Binkley, PharmD, BCIDP, AAHIVPClinical Pharmacy Specialist Infectious DiseaseDepartment of PharmacyPenn Presbyterian Medical CenterPhiladelphia, PennsylvaniaNimish Patel, PharmD, PhD, AAHIVPProfessorDepartment of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of CaliforniaLa Jolla, CaliforniaLink to full program: bit.ly/3ZjSFhg

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:How to input patient specific factors into the HIV-ASSIST toolDiscussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancyAn explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequencyGuidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporatedHow to use the HIV-ASSIST output to guide regimen selection in pregnancyUse of the HIV-ASSIST tool in shared decision-making and patient counselingSonya Krishnan, MD, MHSAssistant ProfessorDivision of Infectious DiseasesJohns Hopkins UniversityBaltimore, MarylandLink to full program: bit.ly/3pwaH2Y

In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:Efficacy data with every-8-week dosingReal-world use in people with viremia Initiation and continuation strategiesVirologic failure dataSafety information Presenter:Ian Frank, MDAssociate ChiefDivision of Infectious DiseasesProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaTo download the slides: https://bit.ly/3HX1GGn To view the full online program: https://bit.ly/3ZjSFhg 

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:Treatment in special populationsREDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumoniaRemdesivir and readmission for COVID-19 in immunocompromised patientsMolnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancyManagement of patients with severe diseaseRECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19Real-world study of tocilizumab vs baricitinib for severe COVID-19Novel antiviralsEnsitrelvirBemnifosbuvir Novel vaccinesNB2155AZD2816/AZD1222qNIV/CoV2373GRT-R910NVX-CoV2373 in people with HIVFaculty:  Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPIProfessor of Microbial DiseasesCentre for Experimental Pathogen Host ResearchUniversity College DublinDublin, IrelandContent based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  Link to full program: bit.ly/3niXGJ6Link to downloadable slides: bit.ly/3LUFejG

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:Gram-negative resistancePharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infectionsComparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremiaReal-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organismsAntimicrobial stewardshipSafety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFYThe SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIsData from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteriaInvestigational agentsOpen-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactamSummary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatmentPost hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs Faculty: David van Duin, MD, PhD, FIDSA, FAST Professor of Medicine Director, Immunocompromised Host Infecious Diseases Program Division of Infectious Diseases University of North Carolina Chapel Hill, North Carolina Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc. Link to full program: https://bit.ly/3niXGJ6Link to downloadable slides: https://bit.ly/3Hx0ppn

In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:Young, healthy patient with no risk factorsYoung, healthy patient with risk factorsOlder patient with immunocompromiseOlder patient with renal dysfunctionPatient experiencing hypoxia Presenters: Tracey Piparo, PA-C Department of Palliative Medicine RJWBarnabas New Brunswick, New Jersey Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: bit.ly/44cgH0qTo view the full online program: https://bit.ly/4201xcO

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:Barriers to HDV screening, including limitations to AASLD guideline recommendationsUse of double reflex testing to improve HDV diagnosisConsiderations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDVUpdated CDC recommendations for HBV screening for all adults using a triple panel test Staging advanced liver disease in patients with HDVIndications for HDV treatment, including patients with low ALT levels and advanced or progressive liver diseaseTreatment landscape for HDVPersonal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosisUpdates on novel HDV therapies, including:Summary of efficacy data on bulevirtide from clinical trialsInterpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib Link to full program: bit.ly/3yp1Lxf